KENNETH BRUCE AIN
Medical Practice in Lexington, KY
License number
Pennsylvania MD027090E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Lexington, KY 40536
Pennsylvania
Pennsylvania
Personal information
See more information about KENNETH BRUCE AIN at radaris.comName
Address
Phone
2336 Abbeywood Rd, Lexington, KY 40515
4725 Inman Dr, Lexington, KY 40513
Lexington, KY
2336 Abbeywood Rd, Lexington, KY 40515
3005 Merideth Cir, Lexington, KY 40513
Professional information
Professor At University Of Kentucky
Position:
Professor of Medicine, Director of Thyroid Oncology Program at University of Kentucky, Director, Thyroid Clinic, Endocrinology Clinic, and Thyroid Cancer Research Laboratory at Veterans Health Administration
Location:
Lexington, Kentucky Area
Industry:
Higher Education
Work:
University of Kentucky
since Jan 1991
-
Professor of Medicine, Director of Thyroid Oncology Program
Veterans Health Administration
since Jan 1991
-
Director, Thyroid Clinic, Endocrinology Clinic, and Thyroid Cancer Research Laboratory
Education:
Brown Medical School 1977 - 1981
M.D., Medicine Brown University 1974 - 1978
B.Sc., Biology
M.D., Medicine Brown University 1974 - 1978
B.Sc., Biology
Interests:
Thyroid Oncology, Thyroidology, Cell Biology, Molecular Biology, Glycoprotein Biochemistry, Epigenetics, Clinical Endocrinology
Dr. Kenneth B Ain, Lexington KY - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism, Endocrinology & Metabolism
Address:
Univ Of Kentucky Endocrinology
740 S Limestone St SUITE 2, Lexington 40536
(859) 323-2232 (Phone)
740 S Limestone St SUITE 2, Lexington 40536
(859) 323-2232 (Phone)
Certifications:
Diabetes, Metabolism & Endocrinology, 1987, Internal Medicine, 1984
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Univ Of Kentucky Endocrinology
740 S Limestone St SUITE 2, Lexington 40536
UK Good Samaritan Hospital
310 South Limestone, Lexington 40508
740 S Limestone St SUITE 2, Lexington 40536
UK Good Samaritan Hospital
310 South Limestone, Lexington 40508
Education:
Medical School
Brown University / Alpert Medical School
Graduated: 1981
Hahnemann U
National Institutes Of Health Clinical Center
University Of Chicago
Brown University / Alpert Medical School
Graduated: 1981
Hahnemann U
National Institutes Of Health Clinical Center
University Of Chicago
Dna Sequence Corresponding To The Minimal Essential Promoter Of The Human Sodium-Iodide Symporter (Hnis)
US Patent:
6015376, Jan 18, 2000
Filed:
Jan 13, 1998
Appl. No.:
9/006186
Inventors:
Kenneth Bruce Ain - Lexington KY
Gopalakrishnan Venkataraman - Lexington KY
Gopalakrishnan Venkataraman - Lexington KY
Assignee:
University of Kentucky Research Foundation - Lexington KY
International Classification:
C07H 2102, C07H 2104, C12Q 168
US Classification:
586 231
Abstract:
Elucidation of the regulation of human sodium-iodide symporter (hNIS) gene expression is critical to understanding its effects on iodide concentration abilities of thyroid and thyroid carcinomas. A 1. 2 kb portion of the 5'-flanking region of the hNIS gene has been isolated and characterized, and the nucleotide sequence for the minimal essential promoter of the hNIS gene is shown in FIG. 1. Transient transfections with chimeric luciferase-reporter constructs into a differentiated human thyroid cell line, KAT-50, as well as non-thyroidal cells, define an active promoter having tissue-specificity. KAT-50 cells expressed hNIS mRNA and were capable of thyrotropin-responsive iodide uptake in vitro.
Kenneth Bruce Ain, Lexington KY
Specialties:
Endocrinologist
Address:
740 S Limestone, Lexington, KY 40508
Education:
Brown University, Warren Alpert Medical School - Doctor of Medicine
National Institutes of Health-Clinical Center - Fellowship - Endocrinology
Bernard Mitchell Hospital-University of Chicago Hospitals - Fellowship - Endocrinology
Hahnemann University Hospital - Residency - Internal Medicine
National Institutes of Health-Clinical Center - Fellowship - Endocrinology
Bernard Mitchell Hospital-University of Chicago Hospitals - Fellowship - Endocrinology
Hahnemann University Hospital - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Endocrinology and Metabolism (Internal Medicine)
Kenneth Ain, Lexington KY
Work:
800 Rose St
800 Rose St, Lexington, KY 40536 UK Dept of Endocrinology
740 S Limestone St, Lexington, KY 40536
800 Rose St, Lexington, KY 40536 UK Dept of Endocrinology
740 S Limestone St, Lexington, KY 40536
Professor At University Of Kentucky Medical Center
Position:
Professor at University of Kentucky Medical Center
Location:
Lexington, Kentucky Area
Industry:
Medical Practice
Work:
University of Kentucky Medical Center
-
Professor
Sodium-Iodide Symporter Gene Repressor Binding Site
US Patent:
2011022, Sep 22, 2011
Filed:
Mar 16, 2010
Appl. No.:
12/724898
Inventors:
Kenneth AIN - Lexington KY, US
Wei Li - Lexington KY, US
Wei Li - Lexington KY, US
International Classification:
A61K 51/00, C07H 21/00, A61K 31/435, C12Q 1/68, A61P 35/00
US Classification:
424 161, 536 221, 514298, 435 614
Abstract:
The present disclosure relates to a sodium iodide symporter (NIS)-repressor binding sites (NRBS) consensus sequence consisting of a DNA molecule having the sequence 5′-T/C(G/A)GCCT(T/C)A(G/A)TTTCCCCA(T/C)CTGT-3′(the “consensus NRBS”). The disclosure further relates to methods of restoring iodide transport in dedifferentiated thyroid cancer cells by interfering with formation or function of the NIS repressor.
Human Consensus Sodium-Iodide Symporter Repressor (Nis-Repressor) Binding Site
US Patent:
2011022, Sep 22, 2011
Filed:
Mar 9, 2011
Appl. No.:
13/044120
Inventors:
Kenneth AIN - Lexington KY, US
Wei Li - Lexington KY, US
Wei Li - Lexington KY, US
International Classification:
C12Q 1/68, C07H 21/04, G01N 27/447
US Classification:
435 61, 536 231, 536 245, 204450
Abstract:
The present disclosure relates to a Sodium-Iodide Symporter-repressor (NIS-repressor) binding site (NRBS) consensus sequence consisting of a DNA molecule having the sequence: 5′-T/C(G/A)GCCT(T/C)A(G/A)TTTCCCCA(T/C)CTGT-3.′ The disclosure further relates to methods of screening compounds and other molecules that bind to or inhibits the NIS-repressor or inhibits or interferes with the binding of NIS-repressor to the NIS-repressor binding site.
Iodine Uptake Restoration In Thyroid Cancer
US Patent:
7029879, Apr 18, 2006
Filed:
Jun 29, 2000
Appl. No.:
09/606042
Inventors:
Kenneth B. Ain - Lexington KY, US
Gopalakrishnan Venkataraman - Lexington KY, US
Gopalakrishnan Venkataraman - Lexington KY, US
Assignee:
University of Kentucky Research Foundation - Lexington KY
International Classification:
C12P 21/24, C12N 5/08
US Classification:
435 703, 435375, 435377
Abstract:
A method of expressing a tumor specific therapeutic response element in a cancerous cell is disclosed in which the response element was previously blocked from expression. The method comprises the step of administering an unblocking agent to the cancerous cell harboring a gene encoding the response element, thereby resulting in the expression of the response element.
Transcriptional Repression Of Sodium-Iodide Symporter In Thyroid Carcinoma
US Patent:
8252912, Aug 28, 2012
Filed:
Apr 21, 2008
Appl. No.:
12/081790
Inventors:
Kenneth Ain - Lexington KY, US
Wei Li - Lexington KY, US
Wei Li - Lexington KY, US
Assignee:
University of Kentucky Research Foundation - Lexington KY
International Classification:
C07H 21/02
US Classification:
536 231
Abstract:
The present disclosure relates to a sodium iodide symporter (NIS)-repressor binding site (NRBS) consisting of a DNA molecule spanning from −645 to −605 nucleotides (SEQ ID NO:4) or from −648 to −620 nucleotides (SEQ ID NO:5) upstream from the translation start site of human NIS gene. The disclosure further relates to a method of restoring iodide transport to a human thyroid carcinoma cell, including: the steps of: i) contacting the cell expressing and forming a NIS repressor protein complex capable of binding to the NRBS of the disclosure with a modulator of said complex, and ii) administering to the cell radiolabeled iodide.